Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CP-101
- Development stage
- Preclinical
- Lead developer
- Clot Protect
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
CP-101 is a first-in-class small molecule direct plasmin inhibitor being developed by Clot Protect (also known as ClotProtect Therapeutics) for the treatment of severe bleeding conditions. As a spin-out from the University of Leeds, Clot Protect designed CP-101 to target plasmin, the serine protease responsible for fibrinolysis (the breakdown of blood clots). By inhibiting plasmin-mediated fibrinolysis, the drug aims to stabilize blood clots and reduce blood loss in acute settings such as trauma and surgery. CP-101 is intended for intravenous administration and is currently in preclinical development, having received SEIS investment from o2h Ventures in 2024.
02
Targets
PLG (Plasminogen)
Beyond the preview
Go deeper on CP-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CP-101.